Evidence map›Paper›PMID 16199306›Full record

ReviewInternational journal of radiation oncology, biology, physics2005

Combining radiotherapy and immunotherapy: a revived partnership.

Sandra Demaria, Nina Bhardwaj, William H McBride, Silvia C Formenti

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of radiation oncology, biology, physics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 197 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
197citing papers in PubMed, 3 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

197 citing papers in PubMed, 3 syntheses or guidelines pooled it, 373 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

137 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sandra DemariaDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA.
Nina Bhardwaj
William H McBride
Silvia C Formenti
New York University · USUniversity of California, Los Angeles · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
Dendritic Cell mediated induction of Anti-HCV immunityR01AI061684 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BHARDWAJ, NINA · 2004 to 2008
$2.9M
Radiation Affects Tumor Antigen PresentationR01CA101752 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCBRIDE, WILLIAM H. · 2003 to 2007
$1.7M
TUMOR APOPTOSIS AS MAJOR DETERMINANT OF IMMUNOGENICITYK08CA089336 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DEMARIA, SANDRA · 2001 to 2006
$684k
NCI NIH HHS 5 P30 CA16087-25NCI NIH HHS K08 CA089336NCI NIH HHS K08 CA89336NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA-101752NCI NIH HHS R01 CA101752NIAID NIH HHS AI061684NIAID NIH HHS R01 AI061684PHS HHS 52731
6 · The paper itself

Abstract

Ionizing radiation therapy (RT) is an important local modality for the treatment of cancer. The current rationale for its use is based largely on the ability of RT to kill the cancer cells by a direct cytotoxic effect. Nevertheless, considerable evidence indicates that RT effects extend beyond the mere elimination of the more radiosensitive fraction of cancer cells present within a tumor at the time of radiation exposure. For instance, a large body of evidence is accumulating on the ability of RT to modify the tumor microenvironment and generate inflammation. This might have far-reaching consequences regarding the response of a patient to treatment, especially if radiation-induced tumor cell kill were to translate into the generation of effective antitumor immunity. Although much remains to be learned about how radiation can impact tumor immunogenicity, data from preclinical studies provide the proof of principle that different immunotherapeutic strategies can be combined with RT to enhance antitumor effects. Conversely, RT could be a useful tool to combine with immunotherapy. This article will briefly summarize what is known about the impact of RT on tumor immunity, including tumor-associated antigens, antigen-presenting cells, and effector mechanisms. In addition, the experimental evidence supporting the contention that RT can be used as a tool to induce antitumor immunity is discussed, and a new approach to radioimmunotherapy of cancer is proposed.

Indexed as

AnimalsAntigen PresentationAntigens, CDAntigens, DifferentiationAntigens, NeoplasmCancer VaccinesClinical Trials, Phase II as TopicCombined Modality TherapyCTLA-4 AntigenCytokinesDendritic CellsHumansImmune SystemImmunotherapyLymphocyte ActivationMiceAntigens, CDAntigens, DifferentiationAntigens, NeoplasmCancer VaccinesCTLA-4 AntigenCTLA4 protein, humanCtla4 protein, mouseCytokines

Identifiers

PMID16199306
PMCPMC1489884
OpenAlexW2160613616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.